NextCure, Inc.
NXTC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $24 | $8 | $9 |
| G&A Expenses | $3 | $3 | $4 | $4 |
| SG&A Expenses | $3 | $3 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $27 | $12 | $12 |
| Operating Income | -$9 | -$27 | -$12 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $1 | $1 |
| Pre-Tax Income | -$9 | -$27 | -$11 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$27 | -$11 | -$12 |
| % Margin | – | – | – | – |
| EPS | -3.22 | -11.29 | -4.703 | -4.972 |
| % Growth | 71.5% | -140.1% | 5.4% | – |
| EPS Diluted | -3.22 | -11.29 | -4.703 | -4.972 |
| Weighted Avg Shares Out | 3 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$8 | -$27 | -$11 | -$12 |
| % Margin | – | – | – | – |